Sunshine Biopharma Incorporated (SBFM)

Over the past six months, Sunshine Biopharma's stock price has declined significantly, underperforming the US Biotechs industry and the US Market over the past year. In October 2025, Sunshine Biopharma approved a $5 million strategic bitcoin investment. In October 2025, the company received FDA-equivalent clearance in Canada for Domperidone and launched Doxycycline and Pravastatin. On February 5, 2026, Dr. Abderrazzak Merzouki resigned as Chief Operating Officer. On February 6, 2026, the stock price gained 4.35%, but was still down by 2.44% for the preceding 10-day period.

Information regarding demand seasonality for Sunshine Biopharma, Inc.'s products and services is not available in the provided search results.

Sunshine Biopharma, Inc. is a pharmaceutical company focused on oncology and antivirals, operating through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter (OTC) Products. The company's drug development programs include SBFM-PL4 for SARS coronavirus infections, Adva-27a for pancreatic cancer, and K1.1 mRNA for liver cancer. It also offers generic prescription drugs in Canada and OTC supplements like Essential 9, Essential Calcium-Vitamin D, L-Citrulline, and Taurine products.

Sunshine Biopharma, Inc. operates in the United States and Canada. The company's headquarters are located in Fort Lauderdale, Florida, USA. It also has a Canadian presence through its wholly-owned subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc., with an office in Pointe-Claire, Quebec, Canada.

In the past year, Sunshine Biopharma's stock performance has been a notable factor in its market perception, with the stock underperforming both the US Biotechs industry and the broader US Market. Analyst sentiment for SBFM is mixed, and the consensus rating score for Sunshine Biopharma is lower than that for other "medical" companies. StockInvest.us upgraded its analysis from a "Strong Sell" to a "Sell" candidate as of February 6, 2026, indicating a negative short-term forecast.

Sunshine Biopharma, Inc.'s ownership is concentrated in individual hands, with Malek Chamoun holding a 75.42% stake as of November 2025. Institutional investors hold a smaller portion of the company's stock, approximately 4.61% of outstanding shares as of late 2025. Major institutional owners and shareholders include Citadel Advisors Llc, Renaissance Technologies Llc, DRW Securities, LLC, Two Sigma Investments, Lp, Two Sigma Securities, Llc, SBI Securities Co., Ltd., Morgan Stanley, UBS Group AG, Advisor Group Holdings, Inc., National Bank Of Canada /fi/, Armistice Capital LLC, Altium Capital Management LLC, and Connective Capital Management LLC.